Archived AES Symposia 2007
Annual Course: Decision Points in Epilepsy - Bedside to Bench
Program Length: 5 hrs 42 min
This symposium is designed to approach important controversies in the treatment of epilepsy. During the lifetime of refractory epilepsy, patients’ questions about treatment choices and patient care arise where the answer is not obvious. The goal of this course is to present the information available in about 20 minutes and then debate the points most important to physicians. A case history will be presented throughout the course.
See learning objectives listed under each faculty presentation.
Basic scientists, epileptologists, practicing neurologists, professionals in epilepsy care, and pharmacists
Opening Remarks and Introduction
of Patient "Sally"
Elinor Ben-Menachem, M.D., Ph.D
When to Start Treatment and with What Evidence
Anthony Marson, M.D
- Evaluate the benefits and harms associated with immediate or deferred AED treatments in patients with single or few seizures, and review how new AEDs compare for longer term efficacy and tolerability in treating patients with a new diagnosis of epilepsy.
Robert Fisher, M.D., Ph.D; Ilo Leppik, M.D
- Discuss the evidence that supports if one seizure is enough or if multiple seizures are necessary to determine if a patient has epilepsy.
Blaise Bourgeois, M.D; Antonio Delgado, M.D
- Discuss the impact of currently available genetic information on epileptic disorders on the treatment of patients.
Raman Sankar, M.D., Ph.D
- Identify available information about animal models of epilepsy and if they indicate when treatment can be safely stopped in human epilepsy.
Peter Camfield, FRCP(C
- Explain the optimal duration of seizure freedom before discontinuing AED treatment, the chances of success and the risks for discontinuation to be followed for intractable epilepsy.
Andrew Cole, M.D., FRCP(C); Samuel Wiebe, M.D
- Interpret the existing data and clinical factors that should guide decisions to continue or discontinue anticonvulsant drug treatment after epilepsy surgery.
Renato Rozental, M.D., Ph.D
- Discuss the rationales for the occurrence of major fetal malformations in humans and how antiepileptic drugs can contribute to their development.
Page Pennell, M.D
- Differentiate between the AEDs’ relative risk for major congenital malformations in children born to women with epilepsy.
Barry Gidal, Pharm.D; Torbjorn Tomson, M.D., Ph.D
- the regulatory and biopharmaceutical criteria for approval of generic drug products, and critique the clinical data regarding both the adequacy and appropriateness of generic substitution of AEDs in patients with epilepsy.
Claude Wasterlain, M.D
- Identify which new drugs are available to treat SE, the potency and pharmocokinetics, risks, and the clinical evidence on which to base treatment.
David Treiman, M.D; James Wheless, M.D
- Describe the treatment of convulsive status epilepticus and express what role, if any, the new AEDs may have in the management of GCSE.
Robert Sloviter, Ph.D
- Differentiate between the features of human temporal lobe epilepsy and those of existing animal models to gain an understanding of how well or how poorly the current models reflect the human neurological condition.
Gregory Cascino, M.D
- Identify treatment options available for children and adults with intractable epilepsy including palliative therapy (corpus callosotomy, VNS, ketogenic or Atkins diet) and/or investigational studies utilizing AES therapy in conjunction with deep brain stimulation or responsive neurostimulation.
Elson So, M.D
- Determine the mechanisms that potentially contribute to SUDEP risk of the patient.
Martin Brodie, M.D; Gregory Holmes, M.D
- Recognize the issues surrounding the available medical knowledge on SUDEP including the potential for prevention coupled with the patient’s and their family’s right to know about the possibility of this catastrophic outcome.
Elinor Ben-Menachem, M.D., Ph.D
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.